Sclerosing epithelioid fibrosarcoma of the bone: a case report of high resistance to chemotherapy and a survey of the literature.
Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft tissue sarcoma mostly occurring in extraosseous sites. SEF represents a clinically challenging entity especially because no standardized treatment regimens are available. Intraosseous localization is an additional challenge with respect to the therapeutical approach. We report on a 16-year-old patient with SEF of the right proximal tibia. The patient underwent standardized neoadjuvant chemotherapy analogous to the EURAMOS-1 protocol for the treatment of osteosarcoma followed by tumor resection and endoprosthetic reconstruction. Histopathological analysis of the resected tumor showed >90% vital tumor cells suggesting no response to chemotherapy. Therefore, therapy was reassigned to the CWS 2002 High-Risk protocol for the treatment of soft tissue sarcoma. To date (22 months after diagnosis), there is no evidence of relapse or metastasis. Our data suggest that SEF may be resistant to a chemotherapy regimen containing Cisplatin, Doxorubicin, and Methotrexate, which should be considered in planning treatment for patients with SEF.
Grunewald
Thomas G P
TG
Department of Pediatrics and Pediatric Oncology Center (POC), Klinikum rechts der Isar, Technische Universität München, Kölner Platz 1, 80804 Munich, Germany.
von Luettichau
Irene
I
Weirich
Gregor
G
Wawer
Angela
A
Behrends
Uta
U
Prodinger
Peter M
PM
Jundt
Gernot
G
Bielack
Stefan S
SS
Gradinger
Reiner
R
Burdach
Stefan
S
Clin Orthop Relat Res. 2008 Jun;466(6):1485-91
18340502
Am J Clin Pathol. 1987 Nov;88(5):615-9
3673943
World J Gastroenterol. 2009 Sep 7;15(33):4204-8
19725160
Pathologe. 1983 May;4(3):135-41
6576329
Ann Pathol. 2000 Mar;20(2):154-7
10740014
Paediatr Drugs. 2002;4(1):21-8
11817983
J Med Case Rep. 2008 Jul 25;2:248
18657268
Cesk Patol. 2001 Nov;37(4):158-62
11813633
Pathol Int. 2002 Feb;52(2):135-40
11940218
Virchows Arch. 2004 Oct;445(4):410-3
15322876
Semin Diagn Pathol. 1993 Nov;10(4):286-91
8140326
Am J Surg Pathol. 2000 Oct;24(10):1353-60
11023096
Am J Surg Pathol. 2001 Jun;25(6):699-709
11395547
Histopathology. 1996 May;28(5):451-5
8735721
Am J Surg Pathol. 1995 Sep;19(9):979-93
7661286
Int J Surg Pathol. 2002 Jul;10(3):227-30
12232581
Eur J Surg Oncol. 2001 Feb;27(1):121-2
11237504
Sarcoma. 2009;2009:953750
19343182
Am J Surg Pathol. 1999 Nov;23(11):1423-8
10555013
Cancer Genet Cytogenet. 2000 Jun;119(2):127-31
10867148
J Clin Pathol. 2004 Jan;57(1):90-4
14693846
Endocr Pathol. 2007 Winter;18(4):233-8
18097772
Curr Treat Options Oncol. 2006 Nov;7(6):444-55
17032557
Cancer Genet Cytogenet. 2004 Jul 15;152(2):136-40
15262433
Cancer. 1970 Nov;26(5):1029-41
5476785
J Clin Pathol. 2001 Sep;54(9):721-3
11533083
Ann Otol Rhinol Laryngol. 2005 Feb;114(2):87-9
15757185
Cancer. 1978 Apr;41(4):1472-87
639005
Histopathology. 1998 Oct;33(4):354-60
9822926
Ultrastruct Pathol. 2003 Sep-Oct;27(5):349-55
14708726
Neurosurgery. 2000 Oct;47(4):956-9; discussion 959-60
11014436
Ultrastruct Pathol. 2001 Jan-Feb;25(1):31-7
11297317
Rev Chir Orthop Reparatrice Appar Mot. 2008 Feb;94(1):92-5
18342037
Cancer Genet Cytogenet. 1998 Dec;107(2):102-6
9844602
Pathologe. 2003 Mar;24(2):103-8
12673498
Skeletal Radiol. 1997 Oct;26(10):619-21
9361360